MétaCan
Menu
Back to cohort
Record W2994034345 · doi:10.1093/noajnl/vdz048

Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop

2019· review· en· W2994034345 on OpenAlexaff
Marta Peñas-Prado, Jing Wu, Daniel P. Cahill, Daniel J. Brat, J Costello, Paul G. Kluetz, J. Gregory Cairncross, Martin J. van den Bent, Roel G.W. Verhaak, Orwa Aboud, Peter C. Burger, Susan M. Chang, Christine Cordova, Raymond Y. Huang, Lindsay Rowe, Martin Taphoorn, Mark R. Gilbert, Terri S. Armstrong, David Aarons, Kevin Camphausen, Elizabeth B. Claus, Brittany Cordeiro, François Ducray, Dominique Figarella-Branger, Pim J. French, Brock Greene, John D. Heiss, Robert B. Jenkins, Amy K. LeBlanc, Tito R. Mendoza, Kathy Oliver, Martha Quezado, Margarita Raygada, Carlos G. Romo, Larry Rubinstein, Christine Siegel, Joohee Sul, Keisuke Ueki, Michael Weller, Patrick Y. Wen, Nicole E. Willmarth, Ying Yuan, Kareem A. Zaghloul

Bibliographic record

VenueNeuro-Oncology Advances · 2019
Typereview
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsUniversity of Calgary
FundersCancer MoonshotMoonshot Research and Development ProgramNational Cancer InstituteNational Institutes of Health
KeywordsOligodendrogliomaMedicineMedical physicsOncologyInternal medicineGliomaCancer researchAstrocytoma

Abstract

fetched live from OpenAlex

BACKGROUND: Oligodendroglioma is a rare primary central nervous system (CNS) tumor with highly variable outcome and for which therapy is usually not curative. At present, little is known regarding the pathways involved with progression of oligodendrogliomas or optimal biomarkers for stratifying risk. Developing new therapies for this rare cancer is especially challenging. To overcome these challenges, the neuro-oncology community must be particularly innovative, seeking multi-institutional and international collaborations, and establishing partnerships with patients and advocacy groups thereby ensuring that each patient enrolled in a study is as informative as possible. METHODS: The mission of the National Cancer Institute's NCI-CONNECT program is to address the challenges and unmet needs in rare CNS cancer research and treatment by connecting patients, health care providers, researchers, and advocacy organizations to work in partnership. On November 19, 2018, the program convened a workshop on oligodendroglioma, one of the 12 rare CNS cancers included in its initial portfolio. The purpose of this workshop was to discuss scientific progress and regulatory challenges in oligodendroglioma research and develop a call to action to advance research and treatment for this cancer. RESULTS: The recommendations of the workshop include a multifaceted and interrelated approach covering: biology and preclinical models, data sharing and advanced molecular diagnosis and imaging; clinical trial design; and patient outreach and engagement. CONCLUSIONS: The NCI-CONNECT program is well positioned to address challenges in oligodendroglioma care and research in collaboration with other stakeholders and is developing a list of action items for future initiatives.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.012
metaresearch head score (Gemma)0.012
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.027
Threshold uncertainty score0.090

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0120.012
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0020.001
Scholarly communication0.0030.001
Open science0.0020.005
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0270.007

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.092
GPT teacher head0.406
Teacher spread0.315 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations14
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-Oncology AdvancesSame topicGlioma Diagnosis and TreatmentFrench-language works237,207